Tianjin Xinglian Peptide Biotechnology

Tianjin Xinglian Peptide Biotechnology is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative peptide-based drugs, particularly Peptide-Drug Conjugates (PDCs) and peptide-targeted radiopharmaceuticals. Leveraging its proprietary Star-Link platform, the company designs high-affinity peptide ligands to deliver therapeutic payloads with high precision to tumor cells. The company's lead programs target well-validated oncology markers such as PSMA for the treatment of metastatic castration-resistant prostate cancer. Based in Tianjin, China, Xinglian Peptide is backed by prominent venture capital firms and aims to advance the field of precision oncology through its versatile peptide engineering capabilities.